Azienda Unita Sanitaria Locale Di Reggio Emilia
- Address
- lock Available on a paid plan
Oncology and Male Urogenital Diseases
At Azienda Unita Sanitaria Locale Di Reggio Emilia, research in neoplasms includes studies focused on prostate cancer and breast cancer. These trials are designed to evaluate whether new treatment strategies can better control disease progression and improve outcomes for patients with advanced or recurrent cancer.
- Biochemically recurrent prostate cancer
- Locally-advanced unresectable or metastatic breast cancer
- Testing new treatment combinations for improved cancer control
The oncology unit is also contributing to research aimed at comparing treatment effectiveness and supporting more personalized care for people with difficult-to-treat cancers.
Cardiovascular Diseases
Clinical research in cardiovascular diseases at this hospital includes work on preventing serious vascular events after acute ischemic stroke and high-risk transient ischemic attack. The main goal is to assess whether a new therapy can reduce the risk of another stroke and improve protection for patients at high risk.
- Acute ischemic stroke and high-risk transient ischemic attack
- Evaluating prevention of recurrent ischemic events
- Improving treatment effectiveness after a recent stroke
This area reflects a strong interest in better secondary prevention and safer long-term care for people with cerebrovascular disease.
Eye Diseases
Research in eye diseases includes studies of uveitic macular edema, a vision-threatening condition linked to inflammation inside the eye. These trials aim to determine whether new treatments can improve visual function and reduce disease impact compared with sham treatment.
- Uveitic macular edema
- Assessing improvement in visual acuity
- Testing a therapy for inflammatory eye disease
The focus is on preserving sight and offering better options for patients living with chronic ocular inflammation.
Cell Physiological Phenomena
The site also participates in research related to cell physiological phenomena, supporting studies that explore how disease behaves at a biological level and how targeted treatments may work in specific patient groups. This type of research helps connect laboratory understanding with practical clinical care.
- Targeted treatment response in cancer and other diseases
- Understanding disease behavior at the cellular level
- Supporting development of more precise therapies
At Azienda Unita Sanitaria Locale Di Reggio Emilia, this broader scientific focus complements the clinical work in oncology, stroke prevention, and ophthalmology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Sanitaria Locale Di Reggio Emilia
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.